News & Updates
Filter by Specialty:
Empagliflozin of little benefit in patients hospitalized for COVID-19
In patients who are hospitalized for COVID-19, treatment with empagliflozin does not appear to have any positive impact on outcomes such as 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death, as shown in the open-label RECOVERY trial.
Empagliflozin of little benefit in patients hospitalized for COVID-19
04 Dec 2023
Ensifentrine improves lung function, cuts exacerbations in COPD
The novel, selective, dual PDE*3 and PDE4 inhibitor ensifentrine improved lung function and reduced exacerbations in individuals with chronic obstructive pulmonary disease (COPD), findings from the ENHANCE**-1 and ENHANCE-2 trials have shown.
Ensifentrine improves lung function, cuts exacerbations in COPD
04 Dec 2023
Gastrointestinal issues linger long after COVID-19 recovery
Gut-brain interaction disorders and persistent gastrointestinal (GI) symptoms prevail 12–18 months following COVID-19 hospitalization, and these prolonged GI issues are associated with the severity of the symptoms during hospitalization and the psychological toll of the illness experience, according to a study.
Gastrointestinal issues linger long after COVID-19 recovery
04 Dec 2023
Simplified, tailored treatment for asthma improves patient outcomes
Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]
